Bonacci R, Gigliotti A, Baudin E, Wion-Barbot N, Emy P, Bonnay M, Cailleux A F, Nakib I, Schlumberger M
Institut Gustave Roussy, Villejuif, France.
Br J Cancer. 1998 Aug;78(4):546-9. doi: 10.1038/bjc.1998.530.
Adrenocortical carcinoma (ACC) is a rare tumour with a poor prognosis. Cisplatin is the most widely tested cytotoxic agent in this disease. A total of 18 patients with advanced ACC were enrolled. Cytotoxic therapy consisted of etoposide (VP16) (100 mg m(-2) day(-1) on days 1-3) and cisplatin (100 mg m(-2) day(-1) on day 1) every 4 weeks. Mitotane treatment was maintained during chemotherapy in 14 patients. A complete response was observed in three cases and a partial response in three cases, giving an overall response rate of 33%. Tumour response was observed in three of the six patients with progressive disease during treatment with mitotane given at an effective dosage, as shown by serum levels >14 mg l(-1). Toxic effects were as expected and were non-life-threatening; no treatment interruption was required.
肾上腺皮质癌（ACC）是一种预后较差的罕见肿瘤。顺铂是在该疾病中测试最广泛的细胞毒性药物。总共招募了18例晚期ACC患者。细胞毒性治疗方案为依托泊苷（VP16）（第1 - 3天，100 mg m⁻² 每日）和顺铂（第1天，100 mg m⁻²），每4周重复一次。14例患者在化疗期间持续使用米托坦治疗。3例患者完全缓解，3例部分缓解，总缓解率为33%。在6例米托坦有效剂量治疗期间病情进展的患者中，有3例观察到肿瘤反应，血清水平>14 mg l⁻¹表明了这一点。毒性作用如预期，无生命危险；无需中断治疗。
